American Society of Hirudotherapy

Draft genome sequences of Hirudo medicinalis and salivary transcriptome of three closely related medicinal leeches

Babenko VV, Podgorny OV, Manuvera VA, Kasianov AS, Manolov AI, Grafskaia EN, Shirokov DA, Kurdyumov AS, Vinogradov DV, Nikitina AS, Kovalchuk SI, Anikanov NA, Butenko IO, Pobeguts OV, Matyushkina DS, Rakitina DV, Kostryukova ES, Zgoda VG, Baskova IP, Trukhan VM, Gelfand MS, Govorun VM, Schiöth HB, Lazarev VN (2020) · BMC Genomics · n=0

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidenceCondition: Venous Congestion in Surgical Flaps →

Study Profile

Design
comparative draft genome and salivary transcriptome analysis of three closely related medicinal leech species (Hirudo medicinalis, H. orientalis, H. verbana) with proteomic verification
Sample size (n)
0
Intervention
Hirudo medicinalis genome annotation + RNA-seq of salivary cells from three Hirudo species + differential gene expression analysis + proteomic verification
Comparator
Cross-species comparison within Hirudo genus
Primary endpoint
Identification of salivary cell-specific gene expression and novel salivary proteins; verification of expression of known anticoagulants
Primary result
First Hirudo medicinalis draft genome reported; identifies novel salivary proteins beyond known anticoagulants; demonstrates that known anticoagulant genes are NOT expressed exclusively in salivary cells; provides updated map of salivary protein-haemostasis interactions
Follow-up duration
Bioinformatic analysis phase
PMID
32349672

Key Findings

  • First Hirudo medicinalis draft genome published
  • Salivary transcriptomes of three Hirudo species characterized
  • Known anticoagulant genes NOT salivary-cell-exclusive
  • Novel salivary proteins identified beyond established anticoagulants
  • Updated salivary protein-haemostasis interaction map

Limitations

  • Draft genome with potential gaps
  • Proteomic verification of subset only
  • Cannot translate genomic findings to clinical applications directly
  • Single Russian institution dominant
  • Limited functional characterization of novel proteins

Clinical Implications

Babenko 2020 provides the foundational genomic resource for Hirudo medicinalis - the species cleared under FDA K040187 for medicinal use in the US. For ASH, this work enables systematic discovery of novel salivary anticoagulants and immunomodulators that may inform future device improvements or pharmaceutical isolates. The genome serves as research infrastructure for the broader leech bioactive compound discovery enterprise.

Related Trials

Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation

McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support

Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)

Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation

Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)

Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review

Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)

← Back to RCT Library

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.